Duke Center for Sexual and Gender Diversity
The DHVI was pleased to have Theaya Willis and Nicholas Antonicci from the Duke Center for Sexual and Gender Diversity (CGSD) join us for an informative presentation on how to create a diverse and inclusive work environment.
Influenza Human Challenge Study Begins at NIAID-Sponsored Clinical Trial Units
A clinical trial in which healthy adults will be deliberately infected with influenza virus under carefully controlled conditions is recruiting volunteers at four Vaccine and Treatment Evaluation Units (VTEUs) supported by NIH’s National Institute of Allergy and Infectious Diseases (NIAID).
New vaccine against tropical disease yellow fever to be tested at the Duke Human Vaccine Institute
A hydrogen peroxide-based vaccine technology that’s already being tested to fight West Nile Virus will now also be studied to combat the tropical disease yellow fever.
Duke Vaccine Institute Plays Integral Role in National Effort to Improve Flu Shots
As part of a massive national effort to improve and modernize flu shots, the Duke Human Vaccine Institute has received three research contracts from the National Institute of Allergy and Infectious Diseases (NIAID), with an initial award of approximately $29.6 million in first-year funding.
Expanding Infectious Disease Response Training to Diverse Worker Populations
Gregory D. Sempowski, Ph.D., is dedicated to helping workers protect themselves during infectious disease emergencies. He leads the Duke Infectious Disease Response Training (DIDRT) program, a five-state consortium funded by the NIEHS Worker Training Program (WTP), to provide up-to-date, high-quality, effective, and efficient biosafety and infectious disease response training.
Duke Human Vaccine Institute Receives Virology Quality Assurance Program Contract
The Duke Human Vaccine Institute has been awarded a contract in the amount of $28.1 million from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to house a virology quality assurance program for laboratories involved in HIV research.
Duke Institute Awarded $129 Million Grant in Ongoing Quest for HIV Vaccine
The Duke Human Vaccine Institute (DHVI) will remain at the lead of the nation’s effort to develop an HIV vaccine, receiving a third, seven-year grant from the National Institute of Allergy and Infectious Diseases totaling at least $129 million.
New Study Works to Understand the Prevalence of Valley Fever
Coccidioidomycosis, also known as “Valley Fever” is an infection caused by Coccidioides, a fungus commonly found in the southwestern region of the United States.
HIV Antibodies learn to Elbow Flex
Behind The Paper blog post by DHVI post-doc, Rory Henderson, for the Nature Research Micrbiology Community. In this post, Dr. Henderson describes the thinking behind his paper, “Selection of immunoglobulin elbow region mutations impacts interdomain conformational flexibility in HIV-1 broadly neutralizing antibodies,” and how the research progressed over time.
Despite evidence, vaccine protests continue
Sixty-five years ago, the polio vaccine developed by Jonas Salk was tested in a landmark efficacy trial. Participants in the trial were called “Polio Pioneers,” and families lined up to receive a vaccine they hoped would prevent their children from contracting this terrifying disease that can cause paralysis and death.